CIBC World Upgrades Atrix Laboratories
Analyst Mara Goldstein raises her rating amid the positive catalyst generated by the FDA's approval of the company's generic version of Benzamycin acne gel
This article is for subscribers only.
Atrix Laboratories (ATRX ) says the Food and Drug Administration reversed its decicion and approved its generic version of an acne gel. CIBC World upgraded the stock.
Analyst Mara Goldstein says she is upgrading Atrix to sector outperform from sector perform on the positive catalyst generated by the FDA's approval of the company's Abbreviated New Drug Application for its generic version of Benzamycin acne gel. She notes expectations for the generics business have been low -- appropriately so in her view.